Tampere spin-off building scalable iPSC-derived corneal cell therapy for limbal stem cell deficiency, targeting first clinical trials around 2027.
Finnish cell therapy — no Korean entity.
Evidence from the records
- “"South Korea"”
- “Ophthalmic cell therapy (cornea)”
- “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
- Intro path
- Founder-to-founder intro via BILIX (network portfolio company of Korea Drug Development Fund (KDDF)).
- First step
- Only with a Korean partner.